Persistence of Antibody Response to N. Meningitidis Group C in Children

Phase 4

Completed

• Conditions: Prevention of Meningococcal Infection

• Registration Number: NCT00316654
• Lead Sponsor: Novartis Vaccines

Brief Summary

Persistence of Antibody Response to N. meningitidis Group C in Children

Detailed Description

Not available

Study Timeline

• Study Start: 2005-02
• Primary Completion: 2005-10
• Study Completion: 2005-10
• Study First Submitted: 2006-04-19
• Study First Submitted QC: 2006-04-19
• Study First Posted: 2006-04-21
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-21
• Last Update Posted: 2017-07-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 489

Inclusion Criteria

• healthy children

Exclusion Criteria

• previous ascertained or suspected disease caused by N. meningitidis
• previous significant acute or chronic infections
• any other serious disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Immunogenicity: serum antibody responses, as measured by bactericidal activity,using hBCA

Secondary Outcome Measures

Name	Time	Method
Evaluate and compare persistence of antibody response to N. meningitidis serogroup C as measured by serum bactericidal activity
safety and tolerability